Based on our previous findings demonstrating trametinib’s efficacy in suppressing HNSCC progression [17], we further investigated molecular alterations associated with the MEK pathway underlying these responses. This evidence concerns the gene MAP2K7 and head and neck squamous cell carcinoma.